Thursday, July 30, 2026
← Back to archivePolicy
Policy•KFF•Jul 29, 2026
Medicare’s Proposed Cut to 340B Drug Payments Would Hit Safety-Net Hospitals While Benefiting For-Profit Hospitals
background ▾
- •CMS proposes cutting Medicare 340B drug reimbursement by 37% (from ASP+6% to ASP-33.4%), with implementation contingent on cost acquisition survey now completed, addressing the Supreme Court's 2022 objection to the prior 2018 rule.
- •The proposal would redistribute $4.85 billion in savings from 340B hospitals to all hospitals via an 8.44% increase in non-drug outpatient service payments, creating winners (for-profit hospitals, non-340B providers) and losers (safety-net hospitals dependent on 340B revenue generation for underserved populations).
- •Monitor finalization timeline and stakeholder litigation risk; safety-net hospital coalitions and the 340B industry are likely to challenge the rule, and any implementation could reshape hospital economics and access to discounted drugs for vulnerable populations.
Centers for Medicare & Medicaid Services (CMS)
→ Read original articlePolicy•Fierce Biotech•Jul 29, 2026
Novo Nordisk fails to dismiss lawsuit over CagriSema readout
background ▾
- •Court ruling that some Novo statements on CagriSema tolerability and trial protocols were 'materially misleading' clears the path for securities litigation to proceed, creating ongoing legal and reputational risk for the company
- •Judge found that Novo's assertion that phase 3 trial protocols were 'substantially identical' to earlier phases contradicted documented evidence of flexible dosing changes—a significant factual vulnerability in Novo's defense
- •Monitor discovery phase for internal communications regarding trial design rationale and whether additional executives face personal liability; assess potential settlement exposure and impact on GLP-1 combination strategy confidence
Novo NordiskCagriSemacagrilintidesemaglutide
→ Read original articlePolicy•STAT News•Jul 30, 2026
Opinion: U.S. dependence on China is a national security risk
background ▾
- •China's state-backed industrial policy—including subsidies estimated at ~4.4% of GDP ($700B annually), technology transfer mandates, and Made in China 2025 designation—has artificially concentrated global pharmaceutical production capacity, not market efficiency alone
- •U.S. policymakers and regulators face pressure to distinguish between domestic regulatory/margin problems and foreign state competition when designing resilience strategies, as conflating them could misdirect policy responses
- •Watch for Congressional action on pharmaceutical supply chain security, potential FDA/CMS policy shifts on generic drug pricing/production incentives, and U.S.-China trade/investment restrictions targeting biopharmaceutical sectors
Policy•STAT News•Jul 30, 2026
Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemption
background ▾
- •Medicaid work requirements affecting millions of low-income Americans begin implementation this week in Nebraska and January 1 across Arkansas, Montana, Iowa, and other states, with preliminary CBO estimates projecting 7+ million coverage losses.
- •The "medically frail" exemption lacks clear definition: beneficiaries must now prove functional impairments prevent 20 hours weekly work and will face enhanced documentation requirements starting 2028, creating bureaucratic barriers for vulnerable populations.
- •Active federal litigation challenges CMS rules published in June versus prior state guidance; outcome could determine medical frailty exemption viability across 20+ states and set precedent for program administration.
Policy•STAT News•Jul 30, 2026
Opinion: Ten years after WHO recognition, mycetoma remains one of the world’s most neglected diseases
background ▾
- •WHO recognition of mycetoma in 2016 has yielded only fragile, insufficient progress due to underfunding and deprioritization of vulnerable populations affected by the disease.
- •DNDi and Eisai's 2017 trial showed fosravuconazole is as effective as itraconazole but requires only once-weekly dosing versus daily dosing, potentially improving patient access and compliance.
- •Burden-of-disease epidemiology studies are underway in Ethiopia, Senegal, India, and Kenya—critical to understanding true mycetoma prevalence and attracting donor and ministerial investment.
Drugs for Neglected Diseases initiative (DNDi)EisaiMycetoma Research Centerfosravuconazoleitraconazole
→ Read original articleMarket Access
Market Access•Fierce Biotech•Jul 30, 2026
J&J pays Sail $785M, charting course to possible in vivo CAR-T buyout
background ▾
- •J&J's $785M upfront + $2.58B acquisition option represents a major competitive escalation in the in vivo CAR-T space, signaling confidence in Sail's circular RNA platform and autoimmune targeting approach after months of data generation
- •In vivo CAR-T therapies are emerging as a potentially superior commercial model compared to ex vivo approaches—avoiding lymphoablation toxicity, reducing manufacturing complexity, and enabling off-the-shelf dosing—making this modality a strategic battleground for major pharma valuations
- •Watch for: SAIL-0839 clinical trial initiation timelines, interim efficacy/safety data in SLE and RA, whether J&J exercises the full acquisition option, and competitive readouts from AbbVie's CPTX2309 and other in vivo CAR-T programs in the same indications
Johnson & JohnsonSail BiomedicinesAbbVieSAIL-0839CPTX2309
→ Read original articleMarket Access•Fierce Biotech•Jul 29, 2026
‘We have what we need to grow:’ Biogen CEO happy to ease off the M&A for a while
background ▾
- •Biogen is deliberately slowing M&A pace to shift focus from portfolio expansion to execution and value creation from existing acquired assets
- •Multiple late-stage clinical readouts expected through 2027, including litifilimab (lupus), felzartamab (antibody-mediated rejection), zorevunersen (Dravet), and diranersen (Alzheimer's)
- •Watch for: litifilimab registrational data by end of 2024 and phase 3 cutaneous lupus data in 2027; CEO confidence in diranersen market potential despite earlier stock volatility; strategic decisions on BIIB091 and broader Alzheimer's portfolio expansion
BiogenApellis PharmaceuticalsAlcyone TherapeuticsSpinrazalitifilimabfelzartamab
→ Read original articleMarket Access•Fierce Biotech•Jul 29, 2026
Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsido
background ▾
- •VT-7208 is explicitly designed to address efficacy, safety, and hepatotoxicity limitations of earlier BTK inhibitors, with phase 1 data suggesting lower therapeutic doses may be achievable—a key competitive advantage against established players like Rhapsido
- •Processa's $200 million funding enables parallel rather than sequential development across three disease indications, significantly accelerating time-to-data and market entry potential compared to typical biotech timelines
- •Watch for phase 2 readouts in food allergy (H1 2028) and CSU (H2 2027) as key inflection points; any hepatotoxicity signal or dosing advantage data could reshape the competitive BTK inhibitor landscape dominated by Novartis, Pfizer, and AbbVie
Processa PharmaceuticalsVidya TherapeuticsNovartisVT-7208Rhapsidocapecitabine
→ Read original articleMarket Access•Fierce Biotech•Jul 29, 2026
‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listing
background ▾
- •CLD-423 is currently first-to-clinic in the TL1A×IL-23p19 bispecific space with phase 1 data showing 80% subcutaneous bioavailability and potential for every 8–12 week dosing; phase 2b in ulcerative colitis and phase 2 open-label in Crohn's planned
- •Reverse merger with PIPE structure reflects market tailwinds for early-stage biotech financing; Caldera secured $278 million when it initially expected only a Series B round, suggesting investor appetite for dual-pathway IBD candidates
- •Competitive landscape intensifying rapidly: Boehringer Ingelheim committed up to €1.05 billion to Simcere's SIM0709 in January; Caldera acknowledges development strategy prioritizes time-to-market and first clinical proof-of-concept to maintain lead
Caldera TherapeuticsSynlogicQyuns TherapeuticsCLD-423Skyrizitulisokibart
→ Read original articleMarket Access•Endpoints News•Jul 29, 2026
Two biotechs sign reverse mergers to advance I&I drug, BTK inhibitor
background ▾
- •Two separate reverse mergers announced to consolidate bispecific antibody and BTK inhibitor programs
- •One transaction involves acquisition of a Chinese bispecific antibody asset; the other involves a BTK inhibitor from Gossamer Bio
Gossamer BioBTK inhibitor
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 30, 2026
Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues
background ▾
- •Sanofi has discontinued three late-stage programs (amlitelimab, balinatunfib, itepekimab) and is conducting a deeper review of the entire late-stage portfolio under new CEO Garijo's leadership, signaling a significant pipeline reset
- •New R&D leadership from Roche and a stated commitment to discontinue underperforming programs based on scientific rigor indicates a fundamental shift in decision-making approach and risk tolerance
- •Sanofi remains open to M&A including potential megadeals (above historical $2-5B target range) to rebuild pipeline, suggesting possible major acquisition announcements within 12 months
SanofiMerck KGaARegeneronamlitelimabbalinatunfibitepekimab
→ Read original articleClinical Trials•Fierce Biotech•Jul 29, 2026
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
background ▾
- •Merck is pursuing a PD-1xVEGF + TROP2 ADC combination strategy (MK-2010 + sac-TMT) in phase 2, positioning to compete in the high-stakes immuno-oncology backbone race as bispecifics threaten to displace Keytruda
- •Merck's measured development pace contrasts sharply with competitors—BioNTech/BMS has 9 pivotal trials underway for pumitamig, Pfizer is rapidly expanding PF-08634404, and China's Minghui is already one year into phase 2 with a similar combination, suggesting Merck risks falling behind in competitive positioning
- •Watch for: accelerated phase 3 initiation for MK-2010 ± sac-TMT pending upcoming clinical data readouts; competitive dynamics in NSCLC and breast cancer as TROP2 ADCs and PD-1xVEGF bispecifics both demonstrate efficacy; and whether Merck's 'wait-and-move' strategy proves prescient or costly
Merck & Co.Summit TherapeuticsAkesoMK-2010sac-TMTivonescimab
→ Read original articleClinical Trials•Fierce Biotech•Jul 29, 2026
FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute
background ▾
- •The core dispute centers on statistical methodology: Capricor claims the FDA improperly evaluated HOPE-3 using an unsigned draft SAP 1.1, while the agency maintains its analytical approach was consistent across all protocol versions and appropriate for the data.
- •The committee found trial results too dependent on specific analytical choices and patient exclusions to support efficacy claims, describing them as 'fragile'—a critical signal of robustness concerns that undermines confidence in the treatment effect.
- •Watch for the FDA's final determination by August 22; the agency has discretion to override the advisory committee's recommendation, particularly if it views the clinical benefit as meaningful despite methodologic concerns, though the 9-3 vote creates substantial headwinds.
CapricorFDAderamiocel
→ Read original articleClinical Trials•Fierce Biotech•Jul 29, 2026
‘Low tech’ chemotherapy nanoparticles show promise for deadly brain tumor recurrence
background ▾
- •Post-resection blood-brain barrier disruption creates a narrow but exploitable therapeutic window (15 minutes to 72 hours) for nanoparticle-delivered chemotherapy to reach glioblastoma margins
- •Use of established liposome technology rather than novel nanoparticles suggests potential for rapid clinical translation and lower development complexity
- •Path forward requires human clinical trials and potential biotech partnerships; efficacy data on recurrence prevention and clinical outcomes remain unknown
University of ManchesterDoxorubicin
→ Read original articleClinical Trials•Endpoints News•Jul 29, 2026
Atea's hep C pill equal to Gilead's; AbCellera inks second deal in two months
background ▾
- •Atea's bemnifosbuvir/ruzasvir combination achieved Epclusa-comparable efficacy in hepatitis C, potentially positioning the company as a competitive threat to Gilead's dominant HCV franchise
- •The limited details in this report suggest the full clinical dataset has not yet been published or presented at a major conference, creating uncertainty around the strength and generalizability of the comparison
- •Monitor for peer-reviewed publication of Atea's HCV trial results, regulatory filing timelines (NDA/BLA), and Gilead's response to competitive pressure in an increasingly mature HCV market
Atea PharmaceuticalsGilead SciencesAbCellerabemnifosbuvirruzasvirEpclusa
→ Read original article